Related references
Note: Only part of the references are listed.Unrelated Cord Blood Transplantation in Adult and Pediatric Acute Lymphoblastic Leukemia: Effect of Minimal Residual Disease on Relapse and Survival
Veronika Bachanova et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia
Francesco Buccisano et al.
BLOOD (2012)
Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation
Chen-Hua Yan et al.
BLOOD (2012)
Prognostic impact of discordant results from cytogenetics and flow cytometry in patients with acute myeloid leukemia undergoing hematopoietic cell transplantation
Min Fang et al.
CANCER (2012)
Minimal residual disease monitoring in childhood acute lymphoblastic leukemia
Dario Campana
CURRENT OPINION IN HEMATOLOGY (2012)
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
U. Platzbecker et al.
LEUKEMIA (2012)
Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP-EBMT analysis
A. Ruggeri et al.
LEUKEMIA (2012)
Clinical significance of minimal residual disease detected by multidimensional flow cytometry: Serial monitoring after allogeneic stem cell transplantation for acute leukemia
Takuya Miyazaki et al.
LEUKEMIA RESEARCH (2012)
High-Throughput Sequencing Detects Minimal Residual Disease in Acute T Lymphoblastic Leukemia
David Wu et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Acute Lymphoblastic Leukemia: Monitoring Minimal Residual Disease as a Therapeutic Principle
Monika Bruggemann et al.
SEMINARS IN ONCOLOGY (2012)
Minimal Residual Disease following Allogeneic Hematopoietic Stem Cell Transplantation
Nicolaus Kroeger et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
Allogeneic Hematopoietic Cell Transplantation with Full-Intensity Conditioning for Adult Acute Lymphoblastic Leukemia: Results from a Single Center, 1998-2006
Kristine Doney et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
Towards individualized follow-up in adult acute myeloid leukemia in remission
Peter Hokland et al.
BLOOD (2011)
High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia
Wing Leung et al.
BLOOD (2011)
The GTPase-activating protein ARAP3 regulates chemotaxis and adhesion-dependent processes in neutrophils
Laure Gambardella et al.
BLOOD (2011)
Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation
Eva Rettinger et al.
BLOOD (2011)
Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia
Anna Candoni et al.
CLINICAL TRANSPLANTATION (2011)
Minimal residual disease markers before and after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia
Alida Dominietto
CURRENT OPINION IN HEMATOLOGY (2011)
Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia
Ron Ram et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia
Roland B. Walter et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Targeted Therapy With the T-Cell-Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, Acute Leukemias, and Myelodysplastic Syndromes
Nicolaus Kroeger et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
Association of Human Development Index with rates and outcomes of hematopoietic stem cell transplantation for patients with acute leukemia
Sebastian Giebel et al.
BLOOD (2010)
Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALL
S. Giebel et al.
BONE MARROW TRANSPLANTATION (2010)
Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993
Bella Patel et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia
Izaskun Elorza et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia
Boglarka Gyurkocza et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial
Jeffrey E. Rubnitz et al.
LANCET ONCOLOGY (2010)
Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008
M. Brueggemann et al.
LEUKEMIA (2010)
Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation
A. C. Lankester et al.
LEUKEMIA (2010)
Progress of Minimal Residual Disease Studies in Childhood Acute Leukemia
Dario Campana
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2010)
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)
Renato Bassan et al.
BLOOD (2009)
High WT1 gene expression before haematopoietic stem cell transplant in children with acute myeloid leukaemia predicts poor event-free survival
David A. Jacobsohn et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation
Martin Bornhaeuser et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Role of Minimal Residual Disease Monitoring in Adult and Pediatric Acute Lymphoblastic Leukemia
Dario Campana
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2009)
Prognostic Value of Minimal Residual Disease Quantification Before Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia: The ALL-REZ BFM Study Group
Peter Bader et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy
David Grimwade et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Monitoring of post-transplant remission of childhood malignancies: is there a standard?
P. Bader et al.
BONE MARROW TRANSPLANTATION (2008)
Minimal residual disease diagnostics in myeloid malignancies in the post transplant period
U. Bacher et al.
BONE MARROW TRANSPLANTATION (2008)
Toward Optimization of Postremission Therapy for Residual Disease-Positive Patients With Acute Myeloid Leukemia
Luca Maurillo et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Acute lymphoblastic leukaemia
Ching-Hon Pui et al.
LANCET (2008)
Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia
M. Paganin et al.
LEUKEMIA (2008)
Monitoring of minimal residual disease in acute myeloid leukemia
Wolfgang Kern et al.
CANCER (2008)
Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia
Alida Dominietto et al.
BLOOD (2007)
Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia
Orietta Spinelli et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2007)
Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99):: benefit of an early intervention
J. Esteve et al.
LEUKEMIA (2007)
Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia
Lucie Sramkova et al.
PEDIATRIC BLOOD & CANCER (2007)
The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia
F. Buccisano et al.
LEUKEMIA (2006)
Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)
B Wassmann et al.
BLOOD (2005)
Elevated levels of WT1 transcripts in bone marrow harvests are associated with a high relapse risk in patients autografted for acute myeloid leukaemia
D Osborne et al.
BONE MARROW TRANSPLANTATION (2005)
Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation
R Zeiser et al.
LEUKEMIA (2005)
Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes
P Kebriaei et al.
BONE MARROW TRANSPLANTATION (2005)
Graft-versus-leukemia effect in acute lymphoblastic leukemia: the importance of tumor burden and early detection
SM Bradfield et al.
LEUKEMIA (2004)
Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: Possible role for pre-emptive immunotherapy?
P Bader et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Minimal residual disease-based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia
S Lee et al.
BLOOD (2003)
Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia:: a report of the Pre-BMT MRD Study Group
O Krejci et al.
BONE MARROW TRANSPLANTATION (2003)
Determination of minimal residual disease in leukaemia patients
D Campana
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation
DL Stirewalt et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2003)
Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation
A Venditti et al.
LEUKEMIA (2003)
Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapse
M Miglino et al.
BONE MARROW TRANSPLANTATION (2002)
Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia -: results of the prospective multicenter LALA-94 trial
H Dombret et al.
BLOOD (2002)
Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL
P Bader et al.
LEUKEMIA (2002)
Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia
FY Mortuza et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation
J Sanchez et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia
M Uzunel et al.
BLOOD (2001)
Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia
VHJ van der Velden et al.
LEUKEMIA (2001)
Minimal residual disease in leukaemia patients
Tomasz Szczepanski et al.
LANCET ONCOLOGY (2001)
Practical application of minimal residual disease assessment in childhood acute lymphoblastic leukaemia
N Goulden et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Share Paper
